Skip to content
Menu

B. Riley Securities Maintains Buy on Veradermics, Raises Price Target to $204

Benzinga Newsdesk 4 weeks ago

Analyst RatingsNewsPrice Target

This page contains a summary, not the full article. Continue to benzinga.com to read the original report.

B. Riley Securities analyst Mayank Mamtani maintains Veradermics (NYSE:MANE) with a Buy and raises the price target from $170 to $204.

B. Riley Securities analyst Mayank Mamtani maintains Veradermics (NYSE:MANE) with a Buy and raises the price target from $170 to $204.

Read at benzinga.com